癌症中的MET变化和MET向治疗:检测策略,治疗效率和新兴技术
Jieun Park1, Chaithanya Chelakkot1, Ji-Hye Nam2
1Research Institute of Pharmaceutical Science, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
Targeted oncology
|July 18, 2025
概括
MET信号通路的失调驱动癌症. 优化MET变化的检测,如突变和放大,是有效的向治疗和改善患者在各种癌症的结果的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 在癌症中,MET信号通路经常通过突变,放大,重新排列和过度表达而失调.
- 转基因抑制剂在固体瘤中显示出临床疗效,特别是非小细胞肺癌 (NSCLC).
研究的目的:
- 审查各种癌症类型中MET变化的频率和临床验证.
- 基于客观反应率 (ORR) 的不同MET向疗法的疗效进行比较.
- 应对MET变化检测方面的挑战,并探索新兴技术.
主要方法:
- 文献综述总结了不同癌症中MET变化的频率.
- 对各种MET抑制剂的客观反应率 (ORR) 的比较分析.
- 讨论检测MET外形14跳转突变和MET放大方面的挑战.
- 探索循环瘤DNA (ctDNA) 和循环瘤细胞 (CTC) 的分析.
主要成果:
- 在各种癌症中,MET变化,包括14元突变,放大和过度表达,是常见的.
- 临床试验显示MET抑制剂 (如crizotinib,capmatinib和tepotinib) 的客观反应率 (ORR) 可以变化.
- 在MET变化检测方法和研究中切断值存在不一致.
- 像ctDNA和CTC分析这样的新兴技术显示出改善检测和响应预测的前景.
结论:
- 针对MET变化的标准化检测方法对于优化向治疗疗效至关重要.
- ctDNA和CTC分析为非侵入性检测,治疗反应预测和抵抗机制识别提供了潜力.
- 需要进一步的研究来完善检测策略,并改善MET向癌症治疗中的患者结果.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.7K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
